The Princess Máxima Center for Pediatric Oncology is a new nationwide research hospital concentrating healthcare, research and education with regard to cancer in children and is located at the Utrecht Science Park de Uithof. The institute has the ambition to give the best treatment to children with cancer with the highest cure rate and the least side effects of (often complex) anti-cancer treatment. The center brings together the best possible care and scientific research, creating a unique comprehensive childhood cancer center in Europe.
The research group of Prof. dr. Monique den Boer (18fte) focusses on the discovery of new (genetic) lesions and targets for precision medicines to improve the clinical outcome for children with acute lymphoblastic leukemia. Our 25-year track record in preclinical/translational research has resulted in knowledge being implemented in new treatment protocols, and our journey continues to further improve the specificity of anti-leukemia treatment. We have expertise in so-called pathobiological studies addressing which (combination of) genetic lesions characterize the patients’ leukemia, how these lesions functionally contribute to therapy resistance and how these lesions affect the behavior of leukemic cells and the interaction with the bone marrow microenvironment. This information is essential to develop strategies that kill leukemic cells more specifically, also given the emerging role for immunotherapeutic strategies like targeting leukemic cells with engineered CAR-T cells.
The research facilities are excellent and state-of-the-art in the new Princess Máxima Center, which opened its doors in 2018 (chief research officer Prof. dr. Alexander Eggermont). The Den Boer group routinely uses many laboratory techniques including different sequencing platforms, lentiviral transduction procedures, flow cytometry and sorting, CSLM imaging, migration assays, drug cytotoxicity studies, and easily implements new innovative technologies like live cell/organel-tracking, metabolomics and single cell sequencing.
Tasks and responsibilities Post Doc
Leukemic cells reside in the complex architecture of the bone marrow compartment. We recently discovered that leukemic cells selectively manipulate this microenvironment as survival strategy, using a.o. tunneling nanotubes. The PostDoc will join the “leukemic niche” team and will investigate which molecules are being exchanged between leukemic cells and the supportive tissue, and will determine which factors promote the survival, expansion and resistance to therapeutic drugs of leukemic cells. To do so, we want to utilize a 3D culture system, where we can mimic the bone marrow microenvironment as much as possible.
Education and skills
We are looking for a molecular trained PostDoc (Junior or Senior). The PostDoc should preferably have experience in 3D cultures and life cell imaging, but also flow cytometry, sorting and primary cell culture. Our group welcomes candidates who are willing to share their knowledge and teach PhD students. The candidate should have excellent communicative skills and a good command of the English language. You are enthusiastic to present and discuss your data in workdiscussions.
You will initially be appointed for a period of 1 year, with a possible extension to 2 years (full-time). Your gross monthly salary will depend on experience and background, starting in scale FWG 65 with 8,33% gross monthly salary holiday allowance and 8,33 % end-of-year bonus. The Princess Máxima Center operates according to the collective labor agreement ‘cao algemene ziekenhuizen’.
Contact and application:
For more information about the job description please contact: Dr. C. van de Ven (email@example.com).
You can apply with a CV and Motivation Letter for this position by pressing the orange apply button “solliciteer direct” on this screen.
Detailed information about the Princess Máxima Center for Pediatric Oncology can also be found at www.prinsesmaximacentrum.nl.
Acquisitie naar aanleiding van deze vacature wordt niet op prijs gesteld.Solliciteer direct